6 active not recruiting. 6 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Topotecan - usual, Topotecan - study - SCLC | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 600 | 2026-10-05 | 2026-10-08 |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC PM8002, Platinum, Etoposide - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 50 | 2023-06-01 | 2025-03-12 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-11-06 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC PM8002, Paclitaxel - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 99 | 2022-05-27 | 2024-12-18 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Olaparib, MEDI4736, Bevacizumab - Ovarian, Breast | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 264 | 2016-03-17 | 2026-07-14 |
Small Cell Lung Carcinoma (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Lymphoma, Large B-Cell, Diffuse (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Breast Diseases (2) · Genital Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
Bevacizumab (1) · Drug Therapy (1) · Etoposide (1) · PM 01183 (1) · Paclitaxel (1) · Platinum (1) · berzosertib (1) · durvalumab (1) · olaparib (1)
Biotheus Inc. (2) · AstraZeneca (1) · Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) · Monte Rosa Therapeutics, Inc (1) · National Cancer Institute (NCI) (1)
United States (4) · China (2) · France (1) · Israel (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Ying Cheng (2) · Anish Thomas, M.D. (1) · Susan Domchek, MD (1)
PMID 32771088, PMID 35756843, PMID 37491889, PMID 37939124
2015 (1)